letermovir + ganciclovir

Letermovir + ganciclovir is a combination antiviral therapy investigated for the prevention and treatment of Cytomegalovirus (CMV) infection, particularly in hematopoietic stem cell transplant (HSCT) or solid organ transplant recipients. Letermovir is a first-in-class CMV DNA terminase complex inhibitor that targets the pUL56 subunit, thereby preventing viral DNA processing and packaging. Ganciclovir is a synthetic nucleoside analogue of 2'-deoxyguanosine that, following intracellular phosphorylation to ganciclovir triphosphate, competitively inhibits CMV DNA polymerase (pUL54), leading to the termination of viral DNA elongation. The combination is studied for its potential to provide enhanced antiviral efficacy by targeting two distinct stages of the CMV replication cycle, potentially allowing for lower doses of ganciclovir to mitigate its associated myelotoxicity. The First Affiliated Hospital of Xian Jiaotong University has sponsored clinical research evaluating this combination regimen in transplant populations.

Other names

Letermovir and ganciclovir combinationLetermovir/ganciclovir